哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效  

Analysis of the efficacy of acid suppression and pulmonary function after clinical treatment with esomeprazole combined with mosapride in patients with asthma combined with acid reflux

作　　者：麦热哈巴·哈力克 艾帕都拉·艾斯拉 赵燕霞[1] 买买提·依斯热依力 魏雪梅[1] 克力木·阿不都热依木[3] Mairehaba·Halike;Aipadula·Aisila;Zhao Yanxia;Maimaiti·Yisireyili;Wei Xuemei;Kelimu·Abudureyimu(Respiratory and Critical Care Medicine Center,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China;Otolaryngology Diagnosis and Treatment Center,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China;Resaerch Center for Minimally Invasive Surgery,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China)

机构地区：[1]新疆维吾尔自治区人民医院呼吸与危重症医学中心,乌鲁木齐830001 [2]新疆维吾尔自治区人民医院耳鼻喉诊疗中心,乌鲁木齐830001 [3]新疆维吾尔自治区人民医院自治区普外微创研究所,乌鲁木齐830001

出　　处：《中华胃食管反流病电子杂志》2023年第4期181-186,共6页Chinese Journal Of Gastroesophageal Reflux Disease(Electronic Edition)

基　　金：新疆维吾尔自治区人民医院院内项目(20190420)。

摘　　要：目的探讨对于哮喘合并酸反流患者临床采用埃索美拉唑联合莫沙必利治疗后抑酸和肺功能的疗效。方法回顾性分析2020年6月至2021年12月在新疆维吾尔自治区人民医院呼吸与危重症医学中心住院的哮喘合并胃食管反流病(GERD)患者(51例),根据治疗方式的不同,进一步分为对照组(给予哮喘常规治疗)和研究组(对照组基础上给予埃索美拉唑联合枸橼酸莫沙必利)。收集患者临床一般信息,肺功能,GERD问卷(GERD-Q),哮喘控制测试(ACT)评分以及呼吸困难量表(mMRC)等相关辅助检查数据。2组患者均进行治疗8周,收集并分析2组患者治疗前后上述指标的改善情况。结果研究组改善酸反流症状(GERD-Q)评分、ACT评分以及mMRC评分指标的程度明显优于对照组,差异均有统计学意义(P<0.05)。2组患者治疗前及治疗后经肺功能检查分析发现,与对照组相比,研究组显著改善患者第一秒用力呼气容积/用力肺活量(FEV1/FVC)、氧分压及二氧化碳分压等指标,差异均有统计学意义(P<0.05)。对照组总有效率为64.00%,研究组为88.46%,差异有统计学意义(P<0.05)。结论采用埃索美拉唑联合枸橼酸莫沙必利治疗哮喘合并GERD效果优于常规治疗,值得进一步临床推广应用。Objective To investigate the efficacy of acid suppression and pulmonary function in patients with asthma combined with acid reflux after clinical treatment with esomeprazole in combination with mosapride.Method Patients with asthma combined with GERD(51 cases)hospitalized in the Respiratory and Critical Care Medicine Center of the People's Hospital of Xinjiang Uygur Autonomous Region from June 2020 to December 2021 were retrospectively analyzed and further divided into a control group(given conventional asthma treatment)and a study group(given esomeprazole combined with mosapride citrate on top of the control group)according to the treatment modality.General clinical information,lung function,GERDQ scale,asthma control test(ACT)score and Medical research association dyspnea scale(mMRC)were collected.Patients in both groups were treated for 8 weeks,and the improvement of the above indicators was collected and analyzed before and after treatment in both groups.Result The improvement of acid reflux symptoms(GERD-Q)score,ACT score,and mMRC score indicators in the research group was significantly better than that in the control group,and the differences were statistically significant(P<0.05).Two groups of patients underwent pulmonary function analysis before and after treatment,and it was found that compared with the control group,the study group significantly improved lung function indicators:first second forced expiratory volume/forced vital capacity(FEV1/FVC),oxygen partial pressure,and carbon dioxide partial pressure.The differences were statistically significant(P<0.05).The total effective rate of the control group was 64.00%,while that of the study group was 88.46%,with a statistically significant difference(P<0.05).Conclusion The use of esomeprazole combined with mosapride citrate in the treatment of asthma combined with GERD is more effective than conventional treatment and deserves further clinical application.

关 键 词：胃食管反流病 哮喘 埃索美拉唑 莫沙必利 疗效 

分 类 号：R562.25[医药卫生—呼吸系统]